Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15332510 | 0.81 | HDAC6 (0.48) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL6990517 | 0.81 | SMN1; SMN2 (0.55) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL2729927 | 0.80 | SMN1; SMN2 (0.61) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL760729 | 0.80 | SMN1; SMN2 (0.57) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL23617657 | 0.79 | SMN1; SMN2 (0.48) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL2676424 | 0.78 | KLK5 (0.57) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL30444890 | 0.78 | KLK5 (0.57) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL3534177 | 0.78 | SMN1; SMN2 (0.56) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL20488181 | 0.78 | HDAC6 (0.48) | HDAC6SMN1; SMN2RECQLLMNAHTT | |
| SCHEMBL11401031 | 0.77 | KLK5 (0.60) | HDAC6SMN1; SMN2RECQLLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2991983-B1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-A]PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2991983-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014177458-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| US-8501750-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120129872-A1 | FUSED HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-8163921-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2265606-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2253630-A1 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2151440-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP1A2 | HDAC6 744/4885SMN1; SMN2 2751/4885RECQL 402/4885 |
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | HDAC6 1288/4885SMN1; SMN2 3937/4885RECQL 2627/4885 |
| US-20120129872-A1 | FUSED HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP3, TIMP3, MMP9 | HDAC6 344/4885SMN1; SMN2 4111/4885RECQL 627/4885 |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HTR3D, PTGDR2, PTGIR | HDAC6 3120/4885SMN1; SMN2 3848/4885RECQL 1924/4885 |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PCSK9, APOB, REN | HDAC6 998/4885SMN1; SMN2 2261/4885RECQL 2729/4885 |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | HDAC6 915/4885SMN1; SMN2 4675/4885RECQL 1628/4885 |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | CNKSR1, HCAR3, HCAR1 | HDAC6 2957/4885SMN1; SMN2 3331/4885RECQL 194/4885 |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTT, HCAR2, HCAR3 | HDAC6 2475/4885SMN1; SMN2 1233/4885RECQL 690/4885 |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | HDAC6 1288/4885SMN1; SMN2 3937/4885RECQL 2627/4885 |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | TBXA2R, HRH2, CYP4F3 | HDAC6 2452/4885SMN1; SMN2 2909/4885RECQL 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.